Stockscreener 앱 받기
4.50
3.64%
-0.17
시간 외 거래:
4.38
-0.12
-2.67%
전일 마감가:
$4.67
열려 있는:
$4.43
하루 거래량:
34,757
Relative Volume:
0.20
시가총액:
$4.49M
수익:
$12.99M
순이익/손실:
$-27.95M
주가수익비율:
-0.00135
EPS:
-3331.1893
순현금흐름:
$-26.12M
1주 성능:
-1.53%
1개월 성능:
-35.53%
6개월 성능:
-85.80%
1년 성능:
-99.52%
1일 변동 폭
$4.38
$4.63
1주일 범위
$4.27
$4.7983
52주 변동 폭
$3.95
$1,299.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.50 | 4.66M | 12.99M | -27.95M | -26.12M | -3,331.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Aptevo to Participate in March 2026 Conferences - Corsicana Daily Sun
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget
Leukemia trial: 86% of older patients benefit, no cytokine release syndrome - Stock Titan
Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - MSN
Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
Retail Surge: Can Moodys Corporation reach resistance levels soon2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
APVO SEC FilingsAptevo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APVOAptevo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aptevo Therapeutics Inc expected to post a loss of $8.10 a shareEarnings Preview - TradingView
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks
Aptevo Therapeutics (NASDAQ: APVO) clears shareholder approval for large Yorkville equity issuance - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Seattle biotech CEO to step down, replacement named - The Business Journals
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest - Defense World
Will Aptevo Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Long-Term Investment Growth Plans - mfd.ru
Will Aptevo Therapeutics Inc. be affected by tariffsCPI Data & AI Based Buy and Sell Signals - mfd.ru
Can Aptevo Therapeutics Inc. navigate macro headwindsJuly 2025 News Drivers & Technical Buy Zone Confirmation - mfd.ru
What is Aptevo Therapeutics Inc.’s valuation compared to sectorM&A Rumor & Accurate Entry/Exit Alerts - mfd.ru
Why Aptevo Therapeutics Inc. stock attracts high net worth investorsProduct Launch & Real-Time Market Sentiment Alerts - mfd.ru
Is Aptevo Therapeutics Inc. stock a value trapQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - mfd.ru
Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Is Aptevo Therapeutics Inc. stock a top momentum playSell Signal & Reliable Entry Point Alerts - mfd.ru
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada
Aptevo Announces CEO Changes - marketscreener.com
Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com
Aptevo Therapeutics Names Jeff Lamothe President and CEO as Marvin White Becomes Executive Chair - citybiz
Is Onto Innovation Inc stock risky to hold now2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Aptevo Therapeutics (APVO) Announces Changes in Leadership to Pr - GuruFocus
Aptevo Therapeutics IncMarvin White to retire as Aptevo CEO effective April 1, 2026SEC filing - marketscreener.com
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):